Sozinibercept Offers Hope for Better Vision to Wet AMD Patients
Julian Upton | | 2 min read | Video
sponsored by Opthea
Fred Guerard, PharmD, CEO of Opthea, outlines the clinical development of sozinibercept in combination with standard-of-care anti-VEGF-A therapies, which has the potential to deliver superior visual outcomes in patients with wet age-related macular degeneration (wet AMD).
Julian Upton is Group Editor of The Ophthalmologist and The New Optometrist. With 20+ years' experience of the magazine industry, he has covered many facets of science and healthcare.